# ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

> **NCT03895944** · EARLY_PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 18 (estimated)

## Conditions studied

- CD19+ Lymphoma, B-Cell
- CD19+ Leukemia, B-Cell

## Interventions

- **BIOLOGICAL:** ET190L1-ARTEMIS™ T cells -iv low dose
- **BIOLOGICAL:** ET190L1-ARTEMIS™ T cells -iv middle dose
- **BIOLOGICAL:** ET190L1-ARTEMIS™ T cells - iv high dose

## Key facts

- **NCT ID:** NCT03895944
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-06
- **Primary completion:** 2019-12-06
- **Final completion:** 2019-12-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2019-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895944, "ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03895944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*